Elekta AB (publ) (OTCMKTS:EKTAY) Announces Earnings Results

Elekta AB (publ) (OTCMKTS:EKTAY) announced its earnings results on Friday. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01), Zacks reports. The firm had revenue of $416.86 million during the quarter, compared to analysts’ expectations of $435.89 million. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%.

Elekta AB (publ) Stock Performance

EKTAY stock opened at $5.60 on Friday. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 22.40 and a beta of 1.22. Elekta AB has a twelve month low of $5.25 and a twelve month high of $8.24. The company has a quick ratio of 0.81, a current ratio of 1.05 and a debt-to-equity ratio of 0.60. The business’s fifty day simple moving average is $5.71 and its two-hundred day simple moving average is $6.09.

Elekta AB (publ) Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, March 27th. Investors of record on Friday, March 7th will be issued a dividend of $0.1072 per share. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s payout ratio is currently 48.00%.

Analyst Ratings Changes

Separately, Sanford C. Bernstein raised shares of Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 29th.

Elekta AB (publ) Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.